{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:08:41Z","timestamp":1791842921674,"version":"4.3.4"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universita degli Studi di Padova","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009414","name":"IOV IRCCS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ctrv.2024.102768","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T02:49:45Z","timestamp":1716432585000},"page":"102768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer"],"prefix":"10.1016","volume":"128","author":[{"given":"Daniela","family":"Scattolin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Dal","family":"Maso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Frega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bonanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102768_b0005","first-page":"12","article-title":"Cancer statistics, 2024","volume":"2024","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2024.102768_b0010","doi-asserted-by":"crossref","unstructured":"Rudin C, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Prim. doi: 10.1038\/s41572-020-00235-0.","DOI":"10.1038\/s41572-020-00235-0"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jtho.2021.08.763","article-title":"Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers","volume":"17","author":"Qu","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102768_b0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102768_b0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102768_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"15","key":"10.1016\/j.ctrv.2024.102768_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14153772","article-title":"Emerging biomarkers and the changing landscape of small cell lung cancer","volume":"14","author":"Keogh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102768_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105338","article-title":"Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation","volume":"25","author":"Pongor","year":"2022","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102768_b0045","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"issue":"January","key":"10.1016\/j.ctrv.2024.102768_b0050","article-title":"Tissue and circulating biomarkers of benefit to immunotherapy in extensive-stage small cell lung cancer patients","volume":"15","author":"Lorenzi","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102768_b0055","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jtho.2020.01.016","article-title":"New approaches to small cell lung cancer therapy: from the laboratory to the clinic John","volume":"15","author":"Poirier","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"175","key":"10.1016\/j.ctrv.2024.102768_b0060","first-page":"88","article-title":"Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification","volume":"2023","author":"Caliman","year":"2022","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102768_b0065","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.molcel.2018.01.012","article-title":"SLFN11 blocks stressed replication forks independently of ATR","volume":"69","author":"Murai","year":"2018","journal-title":"Mol Cell"},{"issue":"7391","key":"10.1016\/j.ctrv.2024.102768_b0070","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"issue":"37","key":"10.1016\/j.ctrv.2024.102768_b0075","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2024.102768_b0080","doi-asserted-by":"crossref","unstructured":"Lok B, Gardner E, Schneeberger V, Al. E. PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 2017. doi: 10.1158\/1078-0432.CCR-16-1040.PARP.","DOI":"10.1158\/1078-0432.CCR-16-1040"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102768_b0085","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.21037\/tlcr-21-437","article-title":"SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer","volume":"10","author":"Kundu","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102768_b0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.dnarep.2015.01.011","article-title":"Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity","volume":"28","author":"Sousa","year":"2015","journal-title":"DNA Repair (Amst)"},{"issue":"17","key":"10.1016\/j.ctrv.2024.102768_b0095","doi-asserted-by":"crossref","first-page":"28575","DOI":"10.18632\/oncotarget.15338","article-title":"Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer","volume":"8","author":"Stewart","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ctrv.2024.102768_b0100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/jir.2012.0133","article-title":"The Schlafen family of proteins and their regulation by interferons","volume":"33","author":"Mavrommatis","year":"2013","journal-title":"J Interf Cytokine Res"},{"issue":"7422","key":"10.1016\/j.ctrv.2024.102768_b0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nature11433","article-title":"Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11","volume":"491","author":"Li","year":"2012","journal-title":"Nature"},{"issue":"51","key":"10.1016\/j.ctrv.2024.102768_b0110","doi-asserted-by":"crossref","first-page":"40333","DOI":"10.1074\/jbc.M110.151076","article-title":"Role of interferon \u03b1 (IFN\u03b1)-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells","volume":"285","author":"Katsoulidis","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102768_b0115","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10549-019-05313-w","article-title":"Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer","volume":"177","author":"Isnaldi","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"September","key":"10.1016\/j.ctrv.2024.102768_b0120","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.2147\/IJGM.S336823","article-title":"Study of clinical predictive value and immune characterization of slfn11 in clear cell renal cell carcinoma","volume":"14","author":"Liu","year":"2021","journal-title":"Int J Gen Med"},{"issue":"January","key":"10.1016\/j.ctrv.2024.102768_b0125","first-page":"1","article-title":"Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy","volume":"12","author":"Hamada","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102768_b0130","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00428-020-02840-6","article-title":"Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq","volume":"478","author":"Takashima","year":"2021","journal-title":"Virchows Arch"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102768_b0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41416-020-01199-4","article-title":"SLFN11 informs on standard of care and novel treatments in a wide range of cancer models","volume":"124","author":"Winkler","year":"2021","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102768_b0140","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41416-022-01811-9","article-title":"Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer","volume":"127","author":"Zhang","year":"2022","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2024.102768_b0145","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1158\/2767-9764.CRC-22-0192","article-title":"SLFN11 negatively regulates noncanonical NF\u03baB signaling to promote glioblastoma progression","volume":"2","author":"Fischietti","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102768_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14102353","article-title":"Can Schlafen 11 help to stratify ovarian cancer patients treated with DNA-damaging agents?","volume":"14","author":"Bednarikova","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102768_b0155","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP Inhibitor activity correlates with slfn11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ctrv.2024.102768_b0160","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102768_b0165","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-021-01476-w","article-title":"A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers","volume":"125","author":"Zhang","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-017-1296-3","article-title":"Report on the first SLFN11 monothematic workshop: From function to role as a biomarker in cancer","volume":"15","author":"Ballestrero","year":"2017","journal-title":"J Transl Med"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102768_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.146098","article-title":"SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer","volume":"6","author":"Winkler","year":"2021","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102768_b0180","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s41416-021-01560-1","article-title":"Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response","volume":"125","author":"Willis","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102768_b0185","article-title":"Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies","author":"Junko","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0190","doi-asserted-by":"crossref","first-page":"94","DOI":"10.15252\/embr.201540964","article-title":"SLFN 11 inhibits checkpoint maintenance and homologous recombination repair","volume":"17","author":"Mu","year":"2016","journal-title":"EMBO Rep"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102768_b0195","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41594-018-0142-5","article-title":"DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs","volume":"25","author":"Li","year":"2018","journal-title":"Nat Struct Mol Biol"},{"issue":"18","key":"10.1016\/j.ctrv.2024.102768_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13184601","article-title":"Precision oncology with drugs targeting the replication stress, ATR, and schlafen 11","volume":"13","author":"Jo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102768_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1073\/pnas.2015654118","article-title":"SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR\/CHK1 inhibitors","volume":"118","author":"Jo","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"10.1016\/j.ctrv.2024.102768_b0210","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1016\/j.celrep.2020.02.117","article-title":"Chromatin remodeling and immediate early gene activation by SLFN11 in response to replication stress","volume":"30","author":"Murai","year":"2020","journal-title":"Cell Rep"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102768_b0215","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1158\/0008-5472.CAN-20-2694","article-title":"SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243","volume":"81","author":"Murai","year":"2021","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102768_b0220","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.7150\/thno.42869","article-title":"SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway","volume":"10","author":"Zhou","year":"2020","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102768_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0212053","article-title":"SLFN11 can sensitize tumor cells towards IFN-\u03b3-mediated T cell killing","volume":"14","author":"Mezzadra","year":"2019","journal-title":"PLoS One"},{"issue":"August","key":"10.1016\/j.ctrv.2024.102768_b0230","first-page":"1","article-title":"Schlafen family is a prognostic biomarker and corresponds with immune infiltration in gastric cancer","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102768_b0235","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.18632\/oncotarget.6413","article-title":"Epigenetic inactivation of the putative DNA\/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs","volume":"7","author":"Nogales","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102768_b0240","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1158\/1078-0432.CCR-17-0443","article-title":"Overcoming resistance to DNA-targeted agents by epigenetic activation of schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors","volume":"24","author":"Tang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13148-020-00876-8","article-title":"Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets","volume":"12","author":"Krushkal","year":"2020","journal-title":"Clin Epigenetics"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102768_b0250","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.ctrv.2024.102768_b0255","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.7150\/jca.32511","article-title":"Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin","volume":"10","author":"Peng","year":"2019","journal-title":"J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-022-01283-x","article-title":"DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection","volume":"14","author":"Markou","year":"2022","journal-title":"Clin Epigenetics"},{"issue":"40","key":"10.1016\/j.ctrv.2024.102768_b0265","doi-asserted-by":"crossref","first-page":"14674","DOI":"10.1074\/jbc.RA118.006588","article-title":"Dephosphorylation activates the interferon-stimulated Schlafen family member 11 in the DNA damage response","volume":"294","author":"Malone","year":"2019","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41416-021-01364-3","article-title":"Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers","volume":"125","author":"Takashima","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1840-6","article-title":"High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment","volume":"15","author":"Deng","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2024.102768_b0280","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-19-0926","article-title":"SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy","author":"Conteduca","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07574-x","article-title":"The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy","volume":"20","author":"Kagami","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2024.102768_b0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13061296","article-title":"Candidate markers of olaparib response from genomic data analyses of human cancer cell lines","volume":"13","author":"Amuzu","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102768_b0295","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1053\/j.gastro.2023.02.005","article-title":"Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti\u2013PD-1 therapy efficacy in hepatocellular carcinoma","volume":"164","author":"Zhou","year":"2023","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102768_b0300","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1158\/1535-7163.MCT-18-0028","article-title":"Novel fluoroindenoisoquinoline non-camptothecin topoisomerase I inhibitors","volume":"17","author":"Marzi","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2024.102768_b0305","first-page":"OF1","article-title":"SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma","volume":"15","author":"Akashi","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"47","key":"10.1016\/j.ctrv.2024.102768_b0310","doi-asserted-by":"crossref","first-page":"76534","DOI":"10.18632\/oncotarget.12266","article-title":"Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition","volume":"7","author":"Murai","year":"2016","journal-title":"Oncotarget"},{"issue":"October","key":"10.1016\/j.ctrv.2024.102768_b0315","first-page":"1","article-title":"Identification of Schlafen-11 as a target of CD47 signaling that regulates sensitivity to ionizing radiation and topoisomerase inhibitors","volume":"9","author":"Kaur","year":"2019","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102768_b0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0224267","article-title":"Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy","volume":"14","author":"Shee","year":"2019","journal-title":"PLoS One"},{"issue":"532","key":"10.1016\/j.ctrv.2024.102768_b0325","first-page":"1","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0330","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/1061186X.2019.1616746","article-title":"SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)","volume":"28","author":"Luan","year":"2020","journal-title":"J Drug Target"},{"issue":"14","key":"10.1016\/j.ctrv.2024.102768_b0335","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/1078-0432.CCR-20-4259","article-title":"Veliparib in combination with carboplatin and etoposide in patients with treatment-Na\u00efve extensive-stage small cell lung cancer: A phase 2 randomized study","volume":"27","author":"Byers","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2024.102768_b0340","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1158\/1535-7163.MCT-11-0252","article-title":"Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells","volume":"10","author":"Soares","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.ctrv.2024.102768_b0345","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells","volume":"15","author":"Nu\u00f1ez","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102768_b0350","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102768_b0355","doi-asserted-by":"crossref","unstructured":"Gupta A, Vaidya KS, Melis JJTM, Hauptschein R, Brock G, Humphreys R. Abstract 2145: High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models. Cancer Res; 83 2145. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-2145.","DOI":"10.1158\/1538-7445.AM2023-2145"},{"issue":"11","key":"10.1016\/j.ctrv.2024.102768_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.155804","article-title":"Targeting genome integrity dysfunctions impedes metastatic potency in non\u2013small cell lung cancer circulating tumor cell\u2013derived explants","volume":"7","author":"Tayoun","year":"2022","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102768_b0365","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1158\/1541-7786.MCR-20-0414","article-title":"AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors","volume":"19","author":"Ramkumar","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2024.102768_b0370","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1535-7163.MCT-20-0351","article-title":"Resistance to pyrrolobenzodiazepine dimers is associated with SLFN11 downregulation and can be reversed through inhibition of ATR","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"1 January","key":"10.1016\/j.ctrv.2024.102768_b0375","first-page":"1","article-title":"Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development","volume":"16","author":"Moribe","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2024.102768_b0380","doi-asserted-by":"crossref","unstructured":"Yin Y Ping, Ma L Ying, Cao G Zhen, Hua J Han, Lv X Tong, Lin W Chu. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11. Acta Pharmacol Sin 2022;43(8):2119\u201327. doi: 10.1038\/s41401-021-00817-y.","DOI":"10.1038\/s41401-021-00817-y"},{"key":"10.1016\/j.ctrv.2024.102768_b0385","doi-asserted-by":"crossref","unstructured":"Raynaud CM, Ahmed EI, Jabeen A, Sanchez A, \u2026 Modulation of SLFN11 induces changes in DNA Damage response. bioRxiv. 2023:1-19. doi: 10.1186\/s12935-023-03144-w.","DOI":"10.1186\/s12935-023-03144-w"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2024.102768_b0390","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2023.41.16_suppl.8504","article-title":"SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC)","volume":"41","author":"Abdel Karim","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2024.102768_b0395","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010004","article-title":"Prognostic significance of slfn11 methylation in plasma cell-free dna in advanced high-grade serous ovarian cancer","volume":"14","author":"Tserpeli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2024.102768_b0400","article-title":"SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer","author":"Byers","year":"2019","journal-title":"Proc 110th Annu Meet Am Assoc Cancer Researc"},{"key":"10.1016\/j.ctrv.2024.102768_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30180-7","article-title":"Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial","author":"Konstantinopoulos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102768_b0410","first-page":"10585","article-title":"Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC)","volume":"2023","author":"Goldman","year":"2022","journal-title":"Poster Sess ASCO"},{"issue":"5","key":"10.1016\/j.ctrv.2024.102768_b0415","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jtho.2020.01.012","article-title":"Sensitivity of mesothelioma cells to PARP inhibitors is not dependent on BAP1 but is enhanced by temozolomide in cells with high-schlafen 11 and low-O6-methylguanine-DNA methyltransferase expression","volume":"15","author":"Rathkey","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2024.102768_b0420","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00432-020-03211-z","article-title":"Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo","volume":"146","author":"van Erp","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2024.102768_b0425","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/15592294.2016.1271853","article-title":"Differential DNA methylation and PM2.5 species in a 450K epigenome-wide association study","volume":"12","author":"Dai","year":"2017","journal-title":"Epigenetics"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:57:44Z","timestamp":1729094264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":85,"alternative-id":["S0305737224000963"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102768","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102768"}}